Fr. 65.00

Fabrication of SR Matrix Tablet for Arthritis Treatment

English, German · Paperback / Softback

Shipping usually within 2 to 3 weeks (title will be printed to order)

Description

Read more

Leflunomide is a disease modifying anti-rheumatic drug (DMARD), which effectively reduces the signs and symptoms of active rheumatoid arthritis (RA) in adults, while inhibiting joint damage and improving physical function. Direct compression was employed for the formulation of tablets. The powder blends of different tablet formulations were screened for preformulation studies like angle of repose, loose bulk density, tapped density, compressibility index and hausner's ratio. The tablets were tested for physical characteristics such as thickness, hardness, friability, weight variation and drug content. The matrix swelling behavior was also investigated. As the time increases, the swelling index was increased; later on it decreases gradually due to dissolution of outermost gelled layer of tablet into dissolution medium. All the evaluated physical parameters of the fabricated tablets were found to be within the acceptable limits.

About the author










Author's vita: Dr. Praveen Kumar, INSPIRE Faculty, CSIR-CSIO, Chandigarh, India. Ms. Pooja Devi, Scientist, CSIR-CSIO, Chandigarh, India. Dr. Mahesh Kumar, Scientist, CSIR-NPL, Delhi, India. Prof. S. M. Shivaprasad, ICMS, JNCASR, Bangalore, India.

Product details

Authors Payal Deepak, Pravee Kumar, Praveen Kumar
Publisher LAP Lambert Academic Publishing
 
Languages English, German
Product format Paperback / Softback
Released 03.07.2017
 
EAN 9783330324664
ISBN 978-3-33-032466-4
No. of pages 96
Subject Natural sciences, medicine, IT, technology > Medicine > Pharmacy

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.